Development Pipeline

Our commitment to pioneering plant-derived therapeutic dermatological treatments is showcased through our robust product pipeline, where cutting-edge research translates into future generations of targeted solutions.

Driven by Professor Chu's core strengths and extensive clinical insights in treating acne, eczema, and psoriasis, our product pipeline is rooted in concepts backed by decades of evidence. This unique foundation allows us to shorten the product development runway and capitalise on the rapid expansion and interest in the plant-derived medical sector.

Our Pipeline

Antimicrobials

Product name
ACN-001
Indications
C. acnes and inflammatory infections
Mechanism
A topical therapeutic specifically designed to target C. acnes bacteria and associated inflammatory conditions. The product leverages our proprietary ACN-Complex which has demonstrated both bacteriostatic and bactericidal properties
Completion target
H1 2026
Status
Open Human Study in progress
Progress
Stage
Product name
ACN-003
Indications
C. acnes infections and excess sebum production
Mechanism
A topical therapeutic. The product utlise our proprietary ACN-Complex and SEB-Complex with a combinatory approach to 5-alpha reductase inhibition and bactericidal activity against C.acnes.
Completion target
H1 2027
Status
Laboratory experimentation and initial in-vivo studies
Progress
Stage
Product name
ECZ-001
Indications
Eczema-prone skin with secondary infections
Mechanism
A dual-action treatment to clear infection and soothe the skin of people suffering from eczema.The product leverages our proprietary ECZ_ Complex which has demonstrated both bacteriostatic and bactericidal efficacy, combined with our Bath and Shower Formula (AST_complex) offering hydration
Completion target
H2 2026
Status
Open Human Study in progress
Progress
Stage
Product name
ECZ-002
Indications
Eczema-prone skin with secondary infection risk
Mechanism
A Topical therapeutic in the form of an antimicrobial and emollient cream. The product leverages our proprietary ECZ_ Complex which has demonstrated both bacteriostatic and bactericidal efficacy, whilst the emollient base provides intensive moisturisation and barrier restoration.
Completion target
H2 2026
Status
Open Human Study in progress
Progress
Stage

Skin Hydrolipid Balance

Product name
ACN-002
Indications
Excess sebum production
Mechanism
A topical therapeutic which is an innovative sebum-regulating formulation that targets excessive oil production through 5-alpha reductase inhibition. The product leverages our proprietary SEB-Complex which in initial in vivo studies have demonstrated a significant level of sebum suppression
Completion target
H1 2026
Status
Open Human Study in progress
Progress
Stage
Product name
AST-001
Indications
For dry, itchy skin.
Mechanism
A Bath and Shower oil, the product leverages our proprietary AST_Complex offering intensive hydration, our bath and shower formula provides immediate relief for dry, itchy skin.
Completion target
H2 2025
Status
Market ready
Progress
Stage
Product name
AST-002
Indications
For dry, itchy skin.
Mechanism
A Topical therapeutic in the form of an anti-inflammatory emollient cream. The product leverages our proprietary AST_Complex whilst the emollient base provides intensive moisturisation and barrier restoration.
Completion target
H2 2026
Status
Ready for open human studies
Progress
Stage

Hair Follicle Regeneration

Product name
ALO-001
Indications
Male Pattern Baldness (androgenetic alopecia)
Mechanism
A topical therapeutic specifically designed as a multi-targeted approach including - 5-alpha reductase inhibition, promotion of growth factor expression, Wnt/B-catenin and Shh signalling pathways, inhibition of Apoptosis & cell proliferation and general improvement of blood circulation. The product leverages our proprietary ALO-Complex
Completion target
-
Status
Research Phase
Progress
Stage
Product name
ALO-002
Indications
Male Pattern Baldness (androgenetic alopecia)
Mechanism
A topical therapeutic specifically designed as a multi-targeted approach including - 5-alpha reductase inhibition, promotion of growth factor expression, Wnt/B-catenin and Shh signalling pathways, inhibition of Apoptosis & cell proliferation and general improvement of blood circulation. The product leverages our proprietary ALO-Complex
Completion target
-
Status
Research Phase
Progress
Stage

Psoriatic Lesion Modulation

Product name
PSO-001
Indications
Psoriatic pruritus with scaling (plaque hyperkeratosis)
Mechanism
A Topical therapeutic in the form of an antimicrobial and emollient cream. The product leverages our proprietary ECZX2_ Complex
Completion target
H1 2028
Status
Early in-vivo studies
Progress
Stage

Bactericidal - Staphylococcal Wound Infection

Product name
WND-001
Indications
Staphylococcal wound infections and associated inflammatory skin conditions.
Mechanism
A targeted topical therapeutic engineered to address Staphylococcus-driven infection. The product leverages our proprietary DermaGuard compound. Designed to disrupt bacterial viability, inhibit proliferation, and reduce microbial burden at the site of infection. Supports modulation of local inflammatory pathways and promotes restoration of epidermal barrier function to facilitate physiological wound repair.
Completion target
H2 2027
Status
Discovery and Mechanistic Research
Progress
Stage

Bactericidal - Impetiginised Eczema

Product name
NCS-001
Indications
Impetiginised eczema and secondary bacterial infections associated with inflammatory dermatoses.
Mechanism
A topical therapeutic to control pathogenic bacterial colonisation in compromised eczematous skin. Reduces microbial load while attenuating inflammation and supporting normalisation of epidermal barrier function. The product leverages our proprietary DermaNCS Compound.
Completion target
H2 2030
Status
Discovery and Mechanistic Research
Progress
Stage

Specialisation

Acne
Alopecia
Asteatosis
Eczema
Psoriasis

Talk to us

Lizzie Hanbury-Tenison

Chief Marketing Officer

Lizzie is the former Head of Marketing, Visual Merchandising, PR & Advocacy at Charlotte Tilbury Beauty, where she played a key role in scaling the brand from pre-revenue to its £1 billion sale, with specialist expertise in brand strategy, PR, advocacy and visual merchandising, and previously served as Head of Digital at Clinique. She brings over 15 years of experience in brand building, marketing and communications, spanning global corporations such as Estée Lauder and Boots, as well as high-growth scale-ups including Charlotte Tilbury. Lizzie is also the co-founder of the award-winning retreat space Cabilla Cornwall (now successfully exited) and Luna Daily, a microbiome-focused skincare brand backed by Unilever Ventures, and currently acts as a strategic advisor to tech start-up Curated Spaces and the charity Thousand Year Trust.
Man in blazer against grey background.

Professor Matt Upton

Advisor

Matt is a Professor of Medical Microbiology at the University of Plymouth and co-founding director at Spectromics and Amprologix. A graduate of the University of Newcastle upon Tyne, Matt is an experienced researcher with a focus on antibiotic candidate discovery, medical microbiology, molecular biology, and biotechnology. He has a demonstrated history of working in higher education and collaborating with industry.
Man in blue shirt, neutral background.

Nicolas Turner

Operations Manager

With over a decade of leadership experience, Nicolas has successfully led operations and project management initiatives across a wide range of industries, including biotech, hospitality, education, construction, and social enterprise. He specializes in steering organizational change and driving business transformation. Known for his strengths in innovation management, process improvement, and organizational development, Nicolas consistently strives for sustainable growth and operational excellence.
Man in black shirt against grey background.

Paul Stanford

Advisor

Paul is a seasoned supply chain and innovation leader with over 37 years of experience leading teams across the global Coca-Cola system. His expertise spans mergers and acquisitions, technical and operational due diligence, post-acquisition integration, and the leadership of product, package and equipment R&D teams. More recently, Paul has been actively mentoring and collaborating with startups in the food sector, bringing his deep industry knowledge to support innovation and growth in emerging businesses.
Man in light shirt, neutral expression.

Nick Kaye

Pharmaceutical Advisor

A third-generation pharmacist, Nick Kaye is known for his dedication to advancing community healthcare. As the Immediate Past Chair of the National Pharmacy Association, he played a key role in shaping national policy and supporting independent pharmacies. Nick is currently the CEO of Community Pharmacy Cornwall and serves as a director at Hendra Pharmacy and Kingsley Muti. Additionally, he is an Independent Non-Executive Director for Wicker Pharmacy in Sheffield, an Ordinary Board member on the Kernow Integrated Care Board, and a Member of the World Pharmacy Council.
Woman in black jacket with necklace.

Kim Lahiri

Product Development Advisor

Kim has 40 years of experience as a cosmetologist and educator. Kim's background in the skincare industry includes product creation, sales, and marketing, with the ability to place new products within the right market. Kim has trained with top skincare houses globally, including Estee Lauder, Prescriptives, Sothys, Rene Guinot, and Academie, focusing on new product development, sales, and marketing. Kim is a member of IFA, CIDESCO, BABTAC, the British Society of Perfumers, and the Society of Cosmetic Scientists.

Philip Fallon

Advisor

A highly experienced accountant, Philip’s worldwide experience includes working for several leading accountancy firms such as Deloitte and Crowe as an Audit Director, overseeing a diverse portfolio that included multiple listed companies. More recently, he has utilised his considerable experience to advise and support start-ups in a wide variety of industries. Philip has an extensive understanding of IFRS, US GAAP reporting, and listed company regulatory compliance.
Man in suit against grey background.

Richard Orchard

Head Of Biochemistry

Richard graduated with honours in Biochemistry from the University of Manchester, embarking on a diverse career in pharmaceuticals. He has held roles at Schering Agrochemicals, The Patterson Institute for Cancer Research, and Phenomenex Inc., contributing to projects ranging from herbicide-plant interactions to brain tumour research and solid phase HPLC extraction packings. In addition, Richard is an active member of the Institute of Biology and the British Mycological Society.
Smartly dressed man in grey suit.

Alex Craven

Chief Operating Officer

Alex is an experienced financial markets professional and proven investor with nearly two decades of success. He brings extensive corporate finance and capital markets knowledge, complemented by hands-on experience in roles including founder, fundraiser, private and public investor, trader, executive board member, reporting issuer, and advisor. In addition, Alex has significant operational expertise, having led and scaled businesses through various stages of growth, optimized internal processes, and overseen both strategic initiatives and day-to-day operations across multiple sectors.
Man in blue shirt, neutral expression.

Philip Mann

Co-Founder / Board Member

Philip brings extensive experience in entrepreneurship, advisory, and consulting services across public and private companies in sectors such as shipping, natural resources, engineering and manufacturing worldwide. He has held senior roles for both private and public firms, including Chief Financial Officer, Executive Vice-President, and board member. Philip has also served in advisory roles to organisations in the US, UK and Scandinavia, providing a breadth of expertise in regulatory reporting and compliance issues.
Man in casual attire, neutral background.

Professor Patric Eriksson

Chief Executive Officer

A Professor of Innovation and seasoned entrepreneur, Patric has founded multiple start-ups and served as Director of Research and Products at a company preparing for an IPO. He also founded a successful business incubator that has supported hundreds of start-ups, several of which achieved exits in the £10–100 million range, co-founded a seed capital firm, and served as a non-executive director and founding team member of Saminvest AB, a government-owned Swedish venture capital company with £360 million under management. In recognition of his impact on entrepreneurship, Patric was awarded the prestigious EU European Enterprise Development Award.
Man in blue striped shirt.

Timothy Sawyer CBE

Chairman / Board Member

Tim has over 30 years of leadership experience in banking and financial services, most recently serving as CEO of the Bank of the Maldives. Prior to that, he was the Chief Investment Officer of Innovate UK, the investment arm of the UK government, and previously held the role of CEO of The Start-Up Loans Company, a key central government initiative supporting early-stage businesses. Tim has also held senior roles at Cahoot and IvoBank, bringing deep expertise in financial strategy and innovation.
Man in smart casual attire smiling.

Professor Tony Chu

Chief Scientific Officer & Co-Founder

Tony is the former head of Dermatology at Imperial College, London and is internationally recognised as a leading authority on acne. He directed an investigative laboratory studying skin carcinogenesis, the immunobiology of acne, and the physiological states of Langerhans cells and cell histiocytosis. Tony also pioneered the use of the NLite laser (2014) as an acne treatment and advanced techniques in percutaneous collagen induction for the treatment of acne scarring.